Pianovich, A
Sarkaria Fenofibrate Triggers bHB Production Regardless of PPARa Expression or Activity Status
Objective: To review the mechanisms of anti-cancer activity of fenofibrate (FF) and other Peroxisome Proliferator Activator Receptor α (PPARα) agonists based on evidences reported in Fenofibrate slow down the growth of xenograft model of triple-negative breast cancer by inducing apoptosis
Fenofibrate, a peroxisome proliferator-activated receptor (PPARα) agonist, is a member of the fibrate class of anti-hyperlipidemic agents and has been widely used in the treatment of different forms of hyperlipidemia and hypercholesterolemia
Fenofibrate is 2-4[(4-chlorobenzoyl) phenoxy]-2-methylpropanoic acid, 1-methylethyl ester (Fig
Higher baseline TG levels lead to a greater TG lowering efficacy of fenofibrate [50,51]
Fenofibrate not only promotes FA-oxidation but also affects the activity of hepatic lipase and lipoprotein lipase
The current study investigated its effect in
It is reported that fenofibrate, a synthetic peroxisome proliferator-activated receptor alpha (PPARa) agonist, induces bHB production in melanoma and glioblastoma cells, as well as in neurospheres composed of non-transformed cells
42±6